Benzinga  Sep 25  Comment 
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular...
Benzinga  Sep 11  Comment 
Investors and analysts don’t seem to be in lockstep when it comes to NewLink Genetics Corp (NASDAQ: NLNK)’s potential. On Monday, the biotech firm secured Buy reiterations from Stifel Nicolaus and Cantor Fitzgerald, and last week, it earned...
Motley Fool  Sep 9  Comment 
Insmed, Newlink Genetics, and Voyager Therapeutics stocks soar on positive news.
Motley Fool  Sep 8  Comment 
On a day when the broader market held relatively steady amid conflicting currents, these stocks rose. Find out why.
Benzinga  Sep 8  Comment 
Kura Oncology Inc (NASDAQ: KURA) shares jumped 91.7 percent to $13.13 after the company offered positive Phase 2 study for tipifarnib in HRAS mutant head and neck cancer. NewLink Genetics Corp (NASDAQ: NLNK) shares gained 30.7 percent to...
Motley Fool  Sep 8  Comment 
Analysts weigh in with positive comments following updated mid-stage trial results for its IDO inhibitor.
Benzinga  Sep 8  Comment 
NewLink Genetics Corp (NASDAQ: NLNK) shares are trading higher by $4.65, or 35 percent, at $18.25 in Friday's session. This comes on top of Thursday's gain of just over $6.00 ($7.79 to $13.60), off positive updates for Indoximod Plus Keytruda...
Motley Fool  Sep 7  Comment 
Updated mid-stage trial results for its IDO-inhibitor are sparking investor optimism.


NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical which develops drugs to help treat cancer patients.[1] The company focuses on immunotherapy - or treatment by causing the immune system to either act or cease to act. In other words, NewLink Genetics attempts to encourage the patients immune system to combat the cancerous cells rather than attempting to kill the cells directly.[2] NewLink Genetics revenues are dependent on the discovery and FDA approval of its therapies.

Business Overview

For the full year 2010, NewLink generated $2.1M in grant revenue. This was an over 100% increase from the $.9M in 2009. Since the company spends heavily on research and development, it still reported a net loss for 2010 of $16.6M. This compares to a net loss of $10.2M in 2009. [3]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on November 10, 2011. The company offered 6.2M shares each for $7. The company had already planned to sell 5.5M shares. However, since they priced below the $10-$12 range, they increased shares. The deal raised a total of $43M. The lead mangers of the deal were Stifel Financial (SF) and Canaccord Genuity.[4]

Trends & Forces

Dependence on FDA approval

As of its IPO, NewLink did not have any FDA approved drugs. It's quite clear that without a completed drug, the company will be unable to produce substantial operating revenue. As a result, the company's performance is limited to actions from the FDA. Furthermore, since NewLink is in the process of developing new, untested treatments, there is no clear guidance for the likelihood of approval or the likelihood that physicians will adopt new treatments.[5]

  1. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Overview p. 1
  2. American Cancer Society - Find Support and Treatment "Immunotherapy"
  3. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Selected Financial Data p. 51
  4. Renaissance Capital - IPO Home "NewLink Genetics prices IPO at $7, below the range" 11 Nov 2011
  5. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Risk Factors" pp. 11-15
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki